Genetic Variability and Biomarkers in Children With Acute Lung Injury (BALI)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01048996|
Recruitment Status : Withdrawn (PI has left institution)
First Posted : January 14, 2010
Last Update Posted : August 24, 2015
Acute Lung Injury (ALI) and the more severe Acute Respiratory Distress Syndrome (ARDS) are a significant problem in Pediatric Intensive Care Units, affecting up to 16 of every 1000 children admitted to these units. These disorders carry with them high mortality rates as well as numerous long-term effects for the surviving children. As the effects of these diseases have significant social and economic ramifications for affected children and their families, research on the development of ALI/ARDS could significantly change how physicians understand the disease and treat patients.
There are a wide range of problems which make certain PICU patients more likely to develop either ALI or ARDS. This research aims to determine which of these children are at the greatest risk for ALI/ARDS by examining differences in plasma biomarkers and in DNA of a large number of PICU patients. We are hypothesizing that significant differences in the level of specific plasma biomarkers or in the frequency of specific DNA variants exist in children who develop ALI/ARDS.
|Condition or disease|
|Acute Respiratory Distress Syndrome Acute Lung Injury|
|Study Type :||Observational|
|Actual Enrollment :||0 participants|
|Observational Model:||Case Control|
|Official Title:||Genetic Variability and Biomarkers in Children With Acute Lung Injury|
|Study Start Date :||October 2009|
|Estimated Primary Completion Date :||June 2013|
|Estimated Study Completion Date :||June 2013|
Those patient who enrolled in the study but did not develop ALI or ARDS during their hospital course.
Those patients who enrolled in the study and developed ALI or ARDS during their hospital course.
- Development of ALI or ARDS [ Time Frame: During PICU stay ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01048996
|United States, Wisconsin|
|Children's Hospital of Wisconsin|
|Milwaukee, Wisconsin, United States, 53226|
|Principal Investigator:||Michael Quasney, PhD, MD||Medical College of Wisconsin|